Pfizer's Bosulif receives conditional marketing authorization from the EC

Pfizer announced that the European Commission has granted conditional marketing authorization for Bosulif in the European Union for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.